Fig. 5: Biomarkers of survival after nivo/chemo and sotiga/chemo and their overlap. | Nature Medicine

Fig. 5: Biomarkers of survival after nivo/chemo and sotiga/chemo and their overlap.

From: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Fig. 5

Venn diagrams of broad categories of circulating biomarkers (top). Left circle shows biomarkers of survival after nivo/chemo; right circle shows biomarkers of survival after sotiga/chemo; and center shows overlapping biomarkers that are associated with survival in both treatment groups. Color indicates direction of association, with blue for higher values associating with longer survival and red for higher values associating with shorter survival by log-rank test. The same structure is shown for tumor biomarkers (bottom).

Back to article page